TriSalus Life Sciences (TLSI) Current Assets (2020 - 2026)

TriSalus Life Sciences has reported Current Assets for 7 years, with the latest figure at $68.1 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 171.51% year-over-year to $68.1 million; the trailing twelve-month figure through Mar 2026 stood at $68.1 million (up 171.51% YoY), and the FY2025 full-year result was $32.2 million, up 56.0% from the prior year.
• Current Assets for Q1 2026 stood at $68.1 million, up from $32.2 million in the prior quarter.
• The five-year high for Current Assets was $68.1 million in Q1 2026, with the low at $161454.0 in Q2 2023.
• Historically, Current Assets has averaged $20.6 million across 5 years, with a median of $20.9 million in 2023.
• Annual changes were most pronounced in 2022 — Current Assets slumped 80.26% — and 2024, when it soared 17205.86%.
• TriSalus Life Sciences' Current Assets stood at $17.2 million in 2022, then rose by 21.19% to $20.9 million in 2023, then slipped by 0.93% to $20.7 million in 2024, then surged by 56.0% to $32.2 million in 2025, then soared by 111.32% to $68.1 million in 2026.
• The last three Current Assets figures came in at $68.1 million (Q1 2026), $32.2 million (Q4 2025), and $33.3 million (Q3 2025), per Business Quant data.